

Press Release

Eurofins Genomics supports ground-breaking research on diabetes in cooperation with the IMI2 INNODIA consortium

Ebersberg, Germany, 03.03.2021:

Eurofins Genomics has provided RNA sequencing for researchers of the IMI2 INNODIA consortium and the data has been published in the prestigious life science journals Cells and Nature.

RNA sequencing, in which the expression of genes and, thereby, the normal and abnormal transcription and gene regulation of specific genes is determined, is a highly important method in the research of diseases. This is particularly true for research of type 1 diabetes, a chronic disease that affects approximately 17 Million people globally. The cause for this disease remains elusive and, therefore, the development of effective measures for prevention are currently unsuccessful.

In an effort to fight type 1 diabetes, 31 academic institutions, six industrial organisations, a small sized enterprise and two patient organisations decided to combine their experience and knowledge and formed the INNODIA consortium. Their joint research effort has already led to a deeper understanding of type 1 diabetes and was published in the leading science journals Nature and Cell Metabolism.

Eurofins Genomics, one of Europe's leading provider of genomics services, contributed to this outstanding research by providing comprehensive RNA sequencing that was done in the modern DNA and RNA sequencing facilities in Galten, Denmark, Ebersberg and Constance, Germany. The services were supported by Sanofi, who provided a considerable budget. More precisely, the provided RNA sequencing was used to investigate the role of proinflammatory cytokines on the β -cell regulatory landscape (<https://doi.org/10.1038/s41588-019-0524-6>), done by Mireia Ramos-Rodríguez and colleagues (2019), the landscape of interferon- α -mediated responses of human pancreatic beta cells (<https://doi.org/10.1038/s41467-020-16327-0>), done by Maikel L. Colli and colleagues (2020), to identify the epitopes presented by beta cells that trigger type 1 diabetes autoimmunity (<https://doi.org/10.1016/j.cmet.2018.07.007>), done by Sergio Gonzalez-Duque and colleagues (2018), and, recently, on the phenomenon that persistent or transient beta cell dysfunction is induced by metabolic stresses (<https://doi.org/10.1016/j.celrep.2020.108466>), done by Lorella Marselli and colleagues (2020).

Please contact Veerle Vanhuyse (media contact, veerle.vanhuyse@kuleuven.be, +32 (0)16 19 38 49) for further reference on INNODIA (<https://www.innodia.eu/>).

For Further Information:

Media Contact: Julian Schlossmacher
Head of Marketing and Communications Eurofins Genomics Europe
+49 8092 8289 925
julianschlossmacher@eurofins.com

Eurofins Genomics Website: www.eurofinsgenomics.com

Notes to Editors:

About Eurofins Genomics – a global leader in genomic products and services Eurofins Genomics, a member of the Eurofins Group with facilities in Europe, the United States and Asia, is an internationally leading provider of DNA sequencing services, next generation sequencing services, genotyping services, DNA synthesis products and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological and research markets. The company's strength is its extensive customer base and high quality services in industrial scale for the life science industries and academic research institutions around the world. For further information, please visit the [Eurofins Genomics website](#).

About Eurofins – the global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter “Eurofins” or “the Group”), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agrosience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over 50,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group’s objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world. Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF FP).